CORT Earnings Date: Nov 3, 2026 (Estimated) — Corcept Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology
Updated
When is CORT's next earnings date?
Corcept Therapeutics Incorporated (CORT) is expected to report earnings on Tuesday, November 3, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.79 on revenue of $323.9M.
How did CORT do in its last earnings report?
In its most recent report on Jul 29, 2026 (Q2 2026), Corcept Therapeutics Incorporated posted EPS of $0.36 versus the $0.02 estimate, a beat of 1700.0%. Revenue was $256.1M against a $219.3M estimate. The stock's 1-day post-earnings move was +27.3%.
How much does CORT stock move after earnings?
CORT beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.5% (up or down) in the day after earnings.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Q2 2026 | 0.02 | 0.36 | +1700.00% | $256.1M | ✅ Beat | +27.29% | +19.09% | +25.80% |
| 2026-04-30 | Q1 2026 | -0.17 | -0.30 | -76.47% | $164.9M | ❌ Miss | +10.53% | +9.74% | +51.42% |
| 2026-02-24 | Q4 2025 | 0.31 | 0.20 | -35.48% | $202.1M | ❌ Miss | -0.71% | -3.29% | +10.94% |
| 2025-11-04 | Q3 2025 | 0.15 | 0.16 | +6.67% | $207.6M | ✅ Beat | +7.81% | +11.13% | +19.07% |
| 2025-07-31 | Q2 2025 | 0.20 | 0.29 | +45.00% | $194.4M | ✅ Beat | +2.72% | +6.42% | +3.80% |
| 2025-02-26 | Q4 2024 | 0.37 | 0.26 | -29.73% | $181.9M | ❌ Miss | -5.55% | -12.43% | -10.56% |
| 2024-10-30 | Q3 2024 | 0.28 | 0.41 | +46.43% | $182.5M | ✅ Beat | +4.44% | +15.65% | +23.01% |
| 2024-07-29 | Q2 2024 | 0.23 | 0.32 | +39.13% | $163.8M | ✅ Beat | -1.12% | -5.53% | -5.12% |
Showing last 8 quarters.